Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track EXOZ with free AI briefings, catalyst countdowns, and dilution alerts.

EXOZ · EXOZYMES INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$5.7M Cash on Hand
10.7mo Cash Runway
Follow EXOZ by email Get an email when EXOZ reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about EXOZ, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

EXOZ holds $5.7M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.6M/quarter from operations, an estimated runway of 10.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 62 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when EXOZ files for a raise →

👥 Who Owns EXOZ

Insiders 64.1% Institutions (10 holders) 1.9% Public and other holders 34%
HolderTypeShares% of sharesAs of
Anthony Digiandomenico
Director, 10% owner · +10,000 options
Insider 3,808,476 40.34% 2026-10-01
Christopher A Marlett
Director, 10% owner · +10,000 options
Includes shares also reported by Anthony Digiandomenico, counted once
Insider 3,808,476 40.34% 2026-10-01
MDB Capital Holdings, LLC
10% owner
Includes shares also reported by Anthony Digiandomenico, counted once
Insider 3,808,476 40.34% 2024-11-08
Tyler Paz Korman
Chief Scientific Officer · +79,104 options
Insider 729,123 7.72% 2026-08-19
Paul Hideo Opgenorth
Vice President, Development
Insider 645,149 6.83% 2026-04-01
James Ulrich Bowie
Director · +10,000 options
Insider 577,910 6.12% 2026-10-01
Mohammad Hayat
President & Chairman of Board, Director
Insider 155,818 1.65% 2024-11-08
Edgardo Javier Rayo
Director · +25,000 options
Insider 77,909 0.83% 2026-10-01
Damien Alan Perriman
Chief Commercial Officer · +185,662 options
Insider 28,692 0.30% 2026-10-09
Michael Heltzen
Chief Executive Officer · +235,817 options
Insider 13,853 0.15% 2026-08-19
Fouad Nawaz
Vice President- Finance · +45,000 options
Insider 9,488 0.10% 2026-09-14

Share count 9,439,915 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full EXOZ picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EXOZ and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.